Halozyme | search
Click here to view Halozyme news from 60+ newspapers.
Bookmark or Share- Halozyme - WikipediaHalozyme Therapeutics is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.
- About Us | HalozymeAt Halozyme, we are focused on innovative and disruptive solutions that provide new therapeutic options that could significantly improve the patient experience.
- Reinventing the patient experience. | HalozymeThe patient is at the forefront of everything we do at Halozyme. With our disruptive drug delivery technologies and robust commercial portfolio, we are committed to reinventing the patient experience by easing the burden of treatment and improving patient outcomes.
- ENHANZE | HalozymeOur ENHANZE technology is based on our patented recombinant human hyaluronidase PH20 enzyme, rHuPH20, which locally degrades hyaluronan (HA) in the subcutaneous (SC) space temporarily removing a barrier to fluid flow. This allows for large volume SC injection with increased dispersion and absorption of co-administered therapies.
- Halozyme Therapeutics, Inc. - Investor RelationsCorporate Overview. At Halozyme, we are focused on new and proven therapeutic approaches. We are driven to bring innovative and disruptive solutions and support to partners with a goal of significantly improving patient experiences, and potentially outcomes, for emerging and established therapies.
More
